Illimis Therapeutics Funding: $63M Raised, Series B (2025)

Illimis Therapeutics is based in Seoul, South Korea. It has raised $63M in total funding. Latest round: Series B.

Illimis Therapeutics funding overview

Illimis Therapeutics is based in Seoul, South Korea. Illimis Therapeutics has raised $63M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in July 2025. The round record for Illimis Therapeutics runs through 2025; nothing later has been disclosed. Investors on record include /DSC Investment/, Woori Venture Partners, Korea Development Bank, Hana Ventures, Aju IB Investment, IMM Investment and 12 others. 18 distinct backers are named across the disclosed rounds.

Illimis Therapeutics at a glance

Total raised
$63M
Latest round
Series B
Latest round date
July 2025
Headquarters
Seoul, South Korea
Notable investors
/DSC Investment/, Woori Venture Partners, Korea Development Bank, Hana Ventures, Aju IB Investment, IMM Investment, LB Investment, GS Ventures

Frequently asked about Illimis Therapeutics funding

How much has Illimis Therapeutics raised?
Illimis Therapeutics has raised $63M in total disclosed funding across the rounds on record.
Who has invested in Illimis Therapeutics?
/DSC Investment/, Woori Venture Partners, Korea Development Bank, Hana Ventures, Aju IB Investment, IMM Investment are named among the investors backing Illimis Therapeutics.
What was the latest Illimis Therapeutics funding round?
The most recent disclosed round is a Series B, announced in July 2025.
Where is Illimis Therapeutics based?
Illimis Therapeutics is based in Seoul, South Korea.
When did Illimis Therapeutics last raise?
The last disclosed Illimis Therapeutics round closed in July 2025 at Series B.

Round data for Illimis Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Seoul and backer lists below.

Companies related to Illimis Therapeutics (18)

Browse related funding lists (9)

Company funding database · Investor directory · Founder database · Mega-rounds 2026

Resources
Join free
Sign Out Dashboard

The Startup Fundraising Platform

Raise funds for your startup

Find the right investors and get real replies — instantly, powered by AI.

  • AI-scored pitch deck
  • Matched investor list
  • Personalized outreach drafts
Join for free

Takes 30 seconds · No credit card · Cancel anytime

See it in action ↓
  • Library
  • Articles
  • Pitch Decks
  • Videos
  • Shorts
  • Profiles
  • Visuals
  • Questions
  • Ask
  • All
  • Seed & Pre-Seed
  • Series A & B
  • Fintech
  • SaaS & Dev Tools
  • Consumer & Social
  • Marketplace & Frontier
  • Mistakes to Avoid
  • Checklist
  • How to Send
  • Design
  • Length
  • Order
  • Storytelling
  • Investor Q&A
  • One-Pager
  • Email Templates
  • Data Room
  • Investor Update
  • Term Sheet
  • SAFE vs Priced
  • Due Diligence
  • Timeline
  • Metrics
  • Valuation
  • Cap Table
  • Pipeline
  • Board
  • Objections
  • References
  • Closing
  • Bridge Round
  • Down Round
  • Secondary Sale
  • Investor Rejection
  • First Meeting
  • Second Meeting
  • Partner Meeting
  • Post-Mortem
  • Update Cadence
  • Angel Round
  • Option Pool Shuffle
  • Fundraise Pause
  • Vetting VCs
  • First 90 Days
  • First Board Meeting
  • Reference Calls
  • NDA Template
  • Bylaws Template
LibraryPitch Deck Examples

Slide-by-slide guide

 

  • Library
  • Articles
  • Pitch Decks
  • Videos
  • Shorts
  • Profiles
  • Visuals
  • Questions
  • Ask
LibraryArticles

•By Alejandro Cremades